The revelation of encouraging clinical research data has caused a notable increase in the share price of Terns Pharmaceuticals, Inc. (NASDAQ: TERN). TERN stock was trading 15.36% higher on the US stock charts at $9.01 as of the most recent check.
Terns Pharmaceuticals Disseminated Positive Trial Information
Terns Pharmaceuticals declared that the first phase of its randomized, double-blind, placebo-controlled research had shown good top-line results. The biopharmaceutical company assessed TERN-601’s pharmacokinetics, tolerability, pharmacodynamics, and safety using a variety of approaches, including single and multiple ascending dosage.
The company administered TERN-601 to healthy but overweight individuals for the duration of the experiment. The trial results indicated that TERN-601 was well tolerated and achieved dose-dependent, statistically significant placebo-adjusted mean weight loss across all three dosages tested during the 28-day MAD study.
The most notable outcome was a 4.9% placebo-adjusted mean weight loss at the highest dosage of 740 mg per day. Additionally, 67% of participants at this top dose experienced a weight loss of 5% or more from their baseline.
Potential As A Leading GLP-1R Agonist
These findings highlight TERN-601’s potential to become a leading GLP-1R agonist, thanks to its promising efficacy, tolerability, and scalability. The data supports TERN-601’s potential role in treating obesity, either as a standalone therapy or in combination with other agents, such as TERN-501 or a GIPR modulator from the TERN-800 series.
Plans For Phase 2 Development
After this Phase 1 research produced encouraging findings, Terns Pharmaceuticals is getting ready to move TERN-601 into Phase 2 clinical trials by 2025. The medication’s once-daily dosage that effectively produces GLP-1R agonism and its tolerability even at high levels point to a promising future for research.
Most adverse effects were moderate, and there were no reports of interruptions or discontinuations due to dosage. The business intends to highlight the encouraging nature of its clinical findings by presenting these data at a forthcoming scientific conference.